StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE), GlaxoSmithKline Company ViiV Healthcare Announces SWORD 100-Week Data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
July 24, 2018 5:54 AM
ViiV Healthcare, a global specialist HIV company established in November 2009 by GlaxoSmithKline (GSK) and Pfizer (NYSE: PFE), today presented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Pfizer (PFE), GlaxoSmithKline Company ViiV Healthcare Highlights Phase III Data at AIDS 2018
July 24, 2018 5:49 AM
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
July 24, 2018 5:38 AM
Pre-Open Movers 07/23: (DDE) (LPNT) (HAS) Higher; (GST) (PETS) (ITW) Lower (more...)
July 23, 2018 9:31 AM
Leap Therapeutics (LPTX) Reports Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer (PFE) to Evaluate Combination of TRX518, Avelumab, and Chemotherapy
July 23, 2018 7:33 AM
Leap Therapeutics (LPTX) Announces Pact with Merck KGaA and Pfizer (PFE) to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors
July 23, 2018 7:31 AM
Pfizer (PFE) Announces FDA Approves for its Neupogen Biosimilar NIVESTYM
July 20, 2018 4:26 PM
Pfizer's (PFE) Biosimilar to Amgen's (AMGN) Neupogen Approved by FDA - Bloomberg
July 20, 2018 3:10 PM